Respiratory Syncytial Virus

Pretreatment drug for RSV-related wheezing also effective after symptoms set in

Published in TB and Outbreaks Week, June 3rd, 2003

Infectious disease specialists at the University at Buffalo have demonstrated a potentially effective treatment to prevent the frequently life-threatening complications that can develop in infants from infection with respiratory syncytial virus (RSV), a significant cause of infant deaths around the world.

Using mice as an animal model, the researchers showed that treatment with the drug zileuton after RSV infection had taken hold reduced the production of proinflammatory compounds called cysteinyl leukotrienes (LT), known to promote the airway congestion and constriction that causes wheezing.

The results were the first to show that inhibition of LT...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (2003-06-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry